Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23487074 | 0.85 | CHRNB2 (0.45) | HTR2AHRH1 | |
| SCHEMBL24853959 | 0.85 | SLC6A4 (0.37) | HTR2AHRH1SLC6A4HTR6 | |
| SCHEMBL23323081 | 0.77 | CHRNB2 (0.47) | HTR6 | |
| SCHEMBL24774829 | 0.76 | TAAR1 (0.39) | HTR2AHRH1SIGMAR1HTR6 | |
| Hydrochloric Acid SCHEMBL11156907 | 0.74 | SIGMAR1 (0.40) | SIGMAR1 | |
| SCHEMBL29535446 | 0.74 | HSD11B1 (0.37) | HRH3 | |
| SCHEMBL24774767 | 0.72 | LIPG (0.38) | SIGMAR1 | |
| SCHEMBL28317516 | 0.71 | GAA (0.44) | — | |
| SCHEMBL28532896 | 0.70 | SLC6A4 (0.40) | HTR2AHRH1SLC6A4 | |
| SCHEMBL24854063 | 0.70 | CHRNA7 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | HTR2A 2862/4885HRH1 4481/4885HRH3 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.